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ABSTRACT 
Introduction of potent antipsychotics for the treatment of schizophrenia not only brought 
changes in the outlook for management of this disorder but also infused optimism and hope. 
However, substantial number of patients fail to respond to conventional antipsychotics thus creat-
ing a class of patients who are termed as treatment resistant, treatment refractory or difficult to 
treat patients. This update focuses on such patients and provides description of various options for 
their management Though atypical antipsychotics offer respite to a vast number of such difficult 
to treat patients, their efficacy is perhaps over-emphasised. Conversely, the potential of psycho-
social therapies in such patients has not been fully exploited. Management of such patients in the 
community is a challenge and in taking up this gauntlet, a judicious mix of pharmacotherapy and 
psychosocial intervention strategies, close monitoring of the patients with a view to detect prodromes 
of relapse and early intervention are likely to play increasingly important part. 
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The Kraepelinian-Bleulerian concept of 
schizophrenia which so heavily dominated 
psychiatric thinking viewed this disorder as a 
chronic and progressively debilitating condition. 
Both Kraepelin and Bleuler believed that in this 
condition, restitution to premorbid level of 
functioning was not possible. However, despite 
evidence to the contrary, somehow," chronicity 
implying poor prognosis and outcome became 
an integral part of criteria for the diagnosis of 
schizophrenia. ' Six month duration of illness", 
an essential feature of diagnostic guideline for 
the diagnosis of schizophrenia of the American 
Psychiatric Association is a reflection of 
extension of this concept in contemporary 
psychiatry. 
In the light of the above mentioned 
perspective, the management of schizophrenia 
was considered difficult. Reviews by Bleuler 
(1978) and Ciompi (1980) showed that treatment 
offered to the patients did not have substantial 
impact and a sizeable number of patients be-
came chronic. A general consensus emerged 
that roughly one third of the patients recovered, 
one third became chronic and the remainder 
followed an in between course. Introduction of 
chlorpromazine in the 50's and later of 
haloperidol and pimozide ushered in an era of 
psychopharmacology which brought optimism. 
Even then it soon became apparent that many 
patients did not derive any benefit from such 
treatment and thus were resistant or refractory 
to treatment. 
Schizophrenia patients who are treatment 
resistant or refractory to treat have now become 
focus of intense research activity particularly 
from psychopharmacology point of view. 
However, in the context of the conceptual i 
thinking about this disorder in which chronicity 
is either implicit or explicit, the notions of 
resistance to treatment or refractoriness to 
treatment become difficult to understand. Thus, 
designating such patients as "difficult to treat" 
may be more appropriate, less emotive and a 
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shade less controversial. This paper focuses on 
issues pertaining to the management of 
difficult to treat patients and takes a look at 
various options available to help such patients. 
Difficult to treat patients 
The term difficult to treat schizophrenia 
patient is broad and includes not only the so 
called resistant or refractory patients, but also 
those patients who for some reasons fail to show 
desired response to therapy be it drug therapy, 
psycho-social therapies or a combination of the 
two. Difficult to treat patients also includes those 
patients who may be non-compliant, aggressive 
and violent. Difficult to treat patients may also 
mean those patients who for some reason evoke 
negative responses from caregivers including 
mental health professionals. In this article, the 
terms difficult to treat, resistant to treat and 
refractory to treatment would be 
interchangeably used. 
In order to formulate an effective 
management strategy for such difficult patients, 
it is essential to have some criteria for calling a 
patient as treatment resistant or refractory. It is 
generally agreed that treatment refractoriness 
refers to assessment of response to 
conventional drug therapy in a given patient. It 
is also generally agreed that treatment 
refractoriness implies that correctly diagnosed 
patients had been given a fair trial of different 
classes of antipsychotics by different routes in 
adequate doses and for adequate length of time 
and, that despite these the patients failed to 
show the desired response. 
Herein lies the first difficulty. There is a 
need to have consensus on how to define 
varying degrees of response to treatment in 
individual patients. Response to treatment in 
schizophrenia patients is not a single 
dimension but has various facets. Clinical 
outcome, psychosocial outcome, work outcome 
and satisfactory attainment of the goals of 
specific therapies or programmes are some of 
the areas, diverse in nature, which reflect 
response to treatment. Thus, when discussing 
refractoriness to treatment, one has to define 
the frame of reference and also operatinalise 
criteria for categorising response. Consensus 
about adequacy of dose and duration of treat-
ment is also needed. 
Factors which make patients difficult to treat 
Many factors make a patient difficult to 
treat. Some of the major factors are as follows: 
1. Inadequate response to conventional antip-
sychotics. 
2. Problems of adverse drug effects. 
3. Problems of compliance. 
4. Problems of comorbid conditions and 
5. Treatment failure-relapse on adequate drug 
dosage. 
1. Inadequate response to conventional 
antipsychotics : After the introduction of 
chlorpromazine as an antipsychotic, many other 
such agents made there way. In a well 
conducted trial, Cole et al. (I966) showed that 
nearly 70% of the study subjects had 
substantial improvement on antipsychotic 
medication. Since then it was generally believed 
that drug therapy had powerful impact on the 
patients though factors predicting response to 
pharmacotherapy were not delineated with any 
degree of confidence. More recent drug trials, 
however, do not support the view that 
antipsychotics.are as beneficial as was 
suggested by earlier investigations. It is now 
generally held that no more than 50% of the 
patients of schizophrenia derive marked 
benefit from these medications (Von Putten et 
al., 1990; Rifkin et al., 1991; McEvoy et al., 
1991). The reasons for this apparent change 
are not clear though changes in nosology, 
stringent and operationalised criteria for 
diagnosis of schizophrenia, thorough patient 
selection for controlled drug trails as well as 
assessments of response, changes in criteria 
for hospitalisation and discharge from in-patient 
care, the potential role of concomitant 
substance abuse and other comorbid conditions 
e.g. depression in diminishing effectiveness of 
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drug therapy are cited as reasons for this 
change. 
In the above context, it is difficult to 
accurately estimate prevalence of difficult to 
treat patients. One approach that has been 
frequently used for such estimates is to survey 
populations of schizophrenia patients and 
ascertain the number of patients who would 
meet eligibility criteria for clozapine therapy. 
Many studies are now available in which this 
approach has been adopted (Terkelsen and 
Grosser, 1990; Essock et al., 1996). The 
estimates of poor or non responders to 
conventional drug therapy as reported by these 
surveys are not uniform and vary from a low of 
18% for in-patients to a high of 60% for the same 
patients population. It is also reported that these 
patients do not differ much on symptomatology 
from those who have responded better to drug 
therapy (Kane et al., 1988, 1995; Liberman et 
al., 1991; Breieretal., 1994). However, there is 
evidence to suggest that patients who have 
abnormalities on brain imaging, soft 
neurological signs or poor premorbid social 
adjustment tend to respond poorly to 
conventional drug therapy (Weinberger et al., 
1980;Pandurangietal., 1989; Vita etal., 1991; 
Liberman et al., 1992, 1993a,b; DeLisi et al., 
1992). It has also been shown that presence of 
antisocial and violent behaviour, irritability and 
aggression in patient makes him more 
difficult to treat (Remington et al., 1993; 
Honigfield etal., 1996) 
2. Problems of adverse drug effects : Short-term 
as well as. long-term use of antipsychotics is 
associated with adverse drug effects which are 
distressing, intolerable and may become 
incapacitating. The adverse drug effects can be 
acute e.g. akathisia or chronic e.g. tardive 
dyskinesia. Various studies-show that the 
prevalence of adverse drug effects in patients 
is quite common and about 20% of the patients 
on long-term neuroleptics develop tardive 
dyskinesia and that every year nearly 5% of 
patients on chronic neuroleptic treatment run 
the risk of developing this serious problem 
(Jeste & Caliguri, 1993; Kane et al., 1995). 
Although in majority of cases these side-effects 
are mild and non-progressive, yet in some these 
are quite severe and disabling resulting in poor 
quality of life. Also, severe and persistent 
abnormal movements in patients are 
stigmatising. Exact estimates of number of 
patients giving up neuroleptic medication 
because of side-effects is not known but it can 
be safely assumed that presence of these 
adverse effects does contribute substantially to 
patients becoming "difficult to treat". It is also 
quite likely that non-compliance in drug 
treatment is because of these distressing side 
effects in majority of cases. 
3. Problems of compliance : One of the most 
frequent reasons for relapse and 
rehospitalisation in patients of schizophrenia is 
noncompliance. For a variety of reasons 
patients come off antipsychotics- some because 
of distress of side-effects, some because of lack 
of insight whilst still psychotic, some because 
of the conviction that as they have been well 
for some time they do not need medicines and 
some because of mistaken notion that they are 
not vulnerable to relapse. Often lack of 
adequate information about the nature of the 
illness, poor awareness of the need to continue 
with medicines despite being well and barren 
preparation of the patients to cope with 
distressing side-effects are the main reasons 
contributing to noncompliance. The net result 
of noncompliance in majority of cases is a diffi-
cult to treat patient because such patient 
becomes chronic, has relapses and repeated 
hospitalisation. Rates of noncompliance are 
difficult to ascertain, however, as many as 30% 
of the patients become noncompliant in the first 
year of treatment (Kane, 1985) and this figure 
may perhaps be higher for our country because 
of added reasons of financial constraints on the 
part of patients and poor accessibility of 
psychiatric services. 
4. Problems of comorbid conditions : It is now 
increasingly becoming obvious, particularly in 
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the West, that a sizeable number of 
schizophrenia patients abuse drugs such as 
alcohol and cocaine. Many surveys of 
schizophrenia patient populations put these 
figure to range from 47% to 56% for substance 
abuse and 17% to 27% for cocaine abuse 
(Galanter et al., 1988; Regier et al., 1990; 
Shaneret al., 1993). Substance abuse is known 
to aggravate symptoms of the disease and also 
makes prognosis poorer. Substance abuse 
contributes to poor drug compliance and makes 
the patients more vulnerable to become 
homeless (Drake et al., 1991). Concurrent use 
of substances like amphetamines, cocaine and 
alcohol tend to make patients more aggressive 
and antisocial in addition to worsening of the 
symptoms (Yesavage & Zarcone, 1993). 
Depression, anxiety, panic and obsessive 
compulsive phenomena and disorders 
frequently accompany schizophrenia. These 
comorbid psychiatric disorders confound 
diagnostic and treatment issues. But for 
post-psychotic depression, other conditions 
have not been that well researched. In our 
country, the exact extent of comorbid conditions, 
particularly drug abuse, is not known but its 
occurrence cannot be denied though it is 
probably not as high as that seen in the USA. 
5. Treatment failure-relapse on adequate drug 
dosage: There are many patients who despite 
adequate maintenance therapy and seemingly 
good compliance relapse or have exacerbation 
of symptoms. This has been shown in 
numerous long-term trials of maintenance 
therapy in schizophrenia. These patients are not 
necessarily treatment defaulters but for reasons 
which have still not been elucidated do have 
relapses. There is no evidence to suggest that 
these patients who relapse on maintenance 
therapy have any special clinical, socio-demo-
' graphic or treatment characteristics which make 
them more prone to relapse. Management 
guidelines for such patients who are likely to 
become difficult to treat are not available. 
The above mentioned factors make it 
obvious that many reasons contribute towards 
a patient becoming difficult to treat and that in 
times to come this would become a challeng-
ing problem which needs to be contained. 
Strategies for managing difficult to treat 
patients 
The strategies which are employed to 
deal with difficult to treat patients can be broadly 
grouped as follows: 
1 .Strategies pertaining to classical neuroleptics, 
2. Use of atypical antipsychotics and 
3. Psychosocial management strategies. 
1. Strategies pertaining to classical neuroleptics : 
Since drug noncompliance is often the major 
reason for a patient to become a difficult to treat 
subject, as a first step efforts should be made 
to increase compliance This can be achieved 
by educating the family and the patient about 
the virtues of taking medicines regularly and in 
prescribed doses. This approach does pay divi-
dends many times. Next, the compliance and 
monitoring of the patient can be improved by 
putting him/her on a long acting depot prepara-
tion. If the patient does not take medicines be-
cause of real and distressing side effects, then, 
these should be alleviated by appropriate thera-
peutic measures. Also, the dose of medicines 
should be very carefully titrated so that the low-
est effective dose is taken by the patient and 
thus side-effects are minimised and compliance 
optimised. 
Psychiatrists often consider increasing 
the dose of conventional antipsychotics when 
the patient does not show the desired favour-
able response. Some advocate the use of 
megadoses of antipsychotics. However, there 
is no strong evidence to suggest that 
prescription of such megadoses to patients who 
are otherwise non responsive to standard doses 
is beneficial. On the contrary many 
professionals believe that megadoses of 
neuroleptics may cause side effects and point 
out that cardiotoxicity related to megadoses is 
a dangerous situation. It has been shown that 
systematic reduction of dose of antipsychotics 
from a high level is often beneficial in 
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treatment resistant cases as such an approach 
has been shown to reduce both the symptoms 
and side-effects (Von Putten et al., 1993). 
It is a common clinical practice to 
prescribe combinations of more than one 
antipsychotics to a patient. The consensus view 
of the professionals is that this practice is 
hazardous and undesirable. The Royal College 
of Psychiatrists does not recommend use of 
combination of neuroleptics as a routine and 
suggests that it should be used in a very few 
selected cases where the treating psychiatrist 
utilises years of experience dealing with the 
patient to prescribe him a combination. 
When the above mentioned strategies do 
not pay dividends and when there is clinical 
evidence to suggest that the patient has 
depression, anxiety, episodicity or violence, then 
use of adjuncts such as antidepressants, lithium, 
carbamazepine, ECT and benzodiazepines is 
advocated. 
Though at times it is difficulty to 
differentiate between clinical manifestations of 
depression and negative symptoms in 
schizophrenia, yet clinical experience suggests 
that many patients when given the benefit of 
doubt and are prescribed antidepressants, 
they improve. It has also been shown that 
antidepressants are especially helpful in post 
schizophrenic depression (Meltzer, 1992). 
Lithium has often been used as an 
adjunct in the management of treatment 
resistant schizophrenia cases. Many studies 
testify to effectiveness of lithium in reducing 
psychotic symptoms in patients who only partly 
respond to classical neuroleptics. However, 
when combining lithium with haloperidol, 
caution should be exercised as irreversible 
toxicity is known to occur especially if the 
patients is on high doses of haloperidol. 
In schizophrenia patients who have EEG 
abnormalities or episodes of violence and manic 
symptoms, addition of carbamazepine may be 
helpful. Because of risk of neurtopenia which is 
likely to be aggravated, carbamazepine should 
not be combined with clozapine. 
EC.T has been shown to be of some value 
in treatment resistant cases. However, the 
response to ECT is often transient. The role of 
maintenance ECT in resistant cases is 
debatable but many clinicians believe that in 
resistant cases maintenance ECT is necessary 
to maximise therapeutic benefit to the patient. 
Addition of benzodiazepines to neuroleptics 
helps in reducing psychotic agitation as well 
extra pyramidal symptoms. Some researchers 
believe that benzodiazepines also improve 
hallucinations, delusions, thought disorders and 
social withdrawal. 
2. Atypical antipsychotics : There are many 
antipsychotics which are termed as "atypical" 
because of their chemical structure, unique 
affinity for neuroreceptors, effect on prolactin 
levels, capacity to induce catalepsy in 
experimental animals and property of causing 
less EPS. Sulpiride, clozapine and risperidone 
are well known and well established atypical 
antipsychotics. In addition, olanzapine, 
sertraline and sertindole are establishing 
themselves as newer antipsychotics. All of these 
have been shown to be useful in the 
management of schizophrenia. 
a. Sulpiride: Sulpiride is a benzamide. In vari-
ous clinical trials it has been shown to have 
efficacy equivalent to haloperidol. However, it 
has fewer side effects. Sulpiride in low doses is 
beneficial in treating negative symptoms "and 
because it causes less EPS, it is notably 
helpful in those patients who are sensitive and 
prone to develop extra pyramidal symptoms 
(Farmer & Blewett, 1993). 
b. Clozapine: Introduced in 70s, clozapine was 
observed to be a potent antipsychotic, but its 
tendency to cause agranulocytosis led to its 
downfall. The multicentre Clozaril Collaborative 
Project with its improved system of monitoring' 
and early detection of agranulocytosis showed 
that clozapine was significantly more effective 
than chlorpromazine in a group of patients who 
had earlier shown poor response to classical 
neuroleptics (Kane et al., 1988). This drug trial 
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made it possible to explore 4he role of 
clozapine in treatment resistant cases on a wider 
scale and it soon became apparent that this drug 
had efficacy against negative symptoms 
(Farmer & Blewett, 1993). 
Over the years it has been shown that 
clozapine has clear advantage over other 
currently available drugs with regard to 
management of severely ill but resistant to treat 
patients (Marder & Van Putten, 1988; Kane, 
1992). It is now well established 30% to 60% of 
treatment refractory patients derive substantial 
benefit from prolonged therapy with clozapine. 
It is also well documented that clozapine exerts 
its beneficial effects in both positive and 
negative symptoms (Kane et al., 1988). 
Clozapine has less adverse effects on 
cognitive and psychomotor functions, does not 
cause acute EPS, has lower rates of induced 
tardive dyskinesia and improves quality of life 
(Kane etal., 1988; Lindstrom, 1988; Meltzeret 
al., 1990, Pickeretal., 1992; Lader, 1994). Thus, 
the following categories of schizophrenia 
patients should receive clozapine: 
1. Treatment refractory patients. 
2. Patients with prominent negative symptoms 
not responding to conventional psychopharma-
cology. 
3. Patients who are sensitive to classical 
neuroleptics in terms of developing EPS chiefly 
akathisia or dyskinesia. 
Risk of neutropenia and agranulocytosis 
are the main limitations to the use of clozapine 
and because of these risks close haematologi-
cal monitoring of the patients is necessary. 
Epidemiological surveys of patients on 
clozapine indicate that about 1% of patients 
receiving clozapine develop agranulocytosis 
and that nearly 95% of such agranulocytosis 
develops within the first 20 weeks of treatment 
and the risk falls markedly after the first year of 
treatment. It is also noted that older patients 
i.e. patients 50 years and above are 
substantially more at risk of developing 
agranulocytosis. Females are more prone to 
develop agranulocytosis than males. It should 
also be remembered that the side effect of 
agranulocytosis is not dose dependent (Alvir et 
al., 1993; Atkin, 1994).Production of seizures 
is another distressing and dramatic side-effect 
of clozapine. About 1% to 5% of patients on 
clozapine may develop seizures and this 
side-effect is a dose-related occurrence. 
All in all, the introductfon of clozapine, 
its low side-effect profile and cost-effectiveness 
has brought about considerable change in the 
outlook about the treatment of refractory 
patients. Close haematoiogical monitoring and 
effective control of seizures have enhanced 
acceptance of clozapine by the patients. Though 
data pertaining to symptomatic improvement 
with clozapine are quite impressive, 
psychiatrists have also become aware -of 
general improvement in quality of life of 
patients on clozapine (Green, 1996). 
c.Risperidone : Risperidone, a benzisoxazole 
derivative, has high affinity for both 
dopaminergic and serotonergic receptors. It has 
been shown to be superior than conventional 
antipsychotic and exerts beneficial effects on 
both positive and negative symptoms yet has 
low propensity for producing EPS (Ereshefsky, 
1993; Chouinard & Arnott, 1993). In a 
Canadian Multicentre placebo controlled 
double blind trial, the antipsychotic activity and 
side-effect profile of risperidone was compared 
with haloperidol and placebo. A total of 135 
patients of chronic schizophrenia diagnosed 
according to DSM-III-R criteria participated in 
the study. At the end of 8 week trial, 
risperidone was shown to be superior both in 
clinical efficacy as well as in side-effect profile 
in comparison to haloperidol (Chouinard et al., 
1993). Marder and Meilbach (1994) conducted 
a multi-site double blind controlled study to 
investigate the safety and efficacy of 
risperidone. Another objective of their 
investigation was to determine the optimal dose 
of risperidone. A total of 388 patients entered 
the trial. Patients were randomly assigned to 8 
week's treatment with placebo, one of the four 
doses of risperidone (2, 6,10 or 16 mg/day) or 
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20 mg haloperidol per day. It was shown that 
the optimal daily dose for most schizophrenia 
patients was 6 mg/day and that risperidone was 
superior to placebo or haloperidol in clinical 
efficacy. More and more research evidence 
shows that risperidone is a potent compound in 
alleviating positive and negative symptoms 
which has low incidence of side-effects, is as 
good as clozapine and effective in the long terms 
aswell(Heinrichetal., 1994; Klieseretal., 1995; 
Lindstrom et al., 1995). Thus, risperidone is an 
important agent in the management of 
refractory patients where negative symptoms 
or side-effects are vital considerations. 
Moreover, as this drug does not have serious 
' side effects like neutropenia and seizures and 
as no regular blood monitoring is required, 
risperidone would appear to be a worthy 
alternative to clozapine in the management of 
treatment refractory schizophrenia.. 
3. Psychosocial management strategies : It 
is now increasingly recognised that the notion 
of refractoriness to treatment in schizophrenia 
is not merely restricted to effectiveness of drugs 
in alleviating positive or negative symptoms but 
it also encompasses consideration of 
psychosocial functioning of the patient. There 
are many patients who despite remarkable 
symptomatic (positive and negative symptoms) 
improvement continue to have cognitive, 
behavioural (e.g. disruptive behaviour, 
aggression etc.) or social difficulties that make 
it difficult for them to achieve independent 
community living, desired degree of 
psychosocial rehabilitation or social 
reintegration. Wykes & Carson (1896) regard 
violence, expressed emotions, life events, 
homelessness and cognitive deficits as 
possible psychosocial toxic factors in 
schizophrenia patients that have implications for 
rehabilitation and community care. 
Psychosocial interventions are now regarded as 
essential and integral part of management of 
schizophrenia and not just luxury or worthy 
extras (Kane & McGlashen, 1995). 
Psychosocial interventions focus on two 
types of dysfunctions that the patients have - i) 
specific to schizophrenia (e.g. coping with 
distressing hallucinations and delusions) and ii) 
dysfunctions which are common to many 
chronic and debilitating disorders (e.g. living in 
the family) but are complicated by core features 
of schizophrenia. 
Psychosocial intervention strategies can 
be broadly grouped under three heads: 
1. Individual patient interventions 
2. Family Interventions and 
3. Community based interventions. 
1. Individual Patient Interventions 
a. Enhancement of compliance : One of the 
major reasons for treatment resistant is 
noncompliance on the part of the patients. There 
are multiple reasons for noncompliance and 
attention needs to be given to all these reasons 
to enhance compliance. 
At times patients and their caregivers do 
not fully understand the importance of drug 
therapy. In such situations and perhaps as a 
routine in treatment resistant cases, educating 
the patients and their significant key relatives 
about the nature of the illness, the nature of the 
treatment, the importance of regular intake of 
medicines, adherence to maintenance therapy 
and reaming in regular follow-up improve 
compliance. 
Presence of side-effects or apprehen-
sions of developing side-effects are also 
possible reasons for noncompliance. Here, all 
efforts should be made to minimise, if total 
elimination is not possible, side-effects by 
titration of dose or addition of medicines to 
counteract side-effects. Demonstration that 
side-effects can be minimised or improved, may 
result in better compliance. 
Denial of illness and lack of insight often 
lead to patients not taking medicines or giving 
them up. In such a situation cognitive 
behavioural therapy may be of help. Cognitive 
behavioural therapy helps the patients in 
reattributing their iilness from a delusional 
explanation to a medical/illness explanation 
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where taking treatment and medicines becomes 
more meaningful and practical. Another factor 
| which plays an important part in enhancing 
'compliance is the nature and quality of the 
relationship between the mental health 
professional and the patient. The chances of 
patient remaining compliant are greater in a 
trusting doctor-patient relationship environment. 
In our culture where remedial measures 
i other than medical treatment are often sought 
' for the patient, the issue of compliance assumes 
larger meaning. At times the caregivers take 
\ patients off medicines to seek magico-religious 
* and other forms of non-medical treatments such 
as ayurvedic, homeopathic etc. In such a 
situation, educating the caregivers about the 
virtues of medical treatment with a view to have 
the patient in the follow-up net is an urgent and 
rewarding task. 
Studies have shown compliance 
enhancing effects of counselling and 
psychoeducation to the patients and family 
members. Kemp et al. (1996) have recently 
shown promising results of their method of 
"motivational interviewing" in enhancing 
; compliance. 
lb. Psychotherapies : Cognitive Behavioural 
I Therapy (CBT): 
i Many researchers have developed treat-
1 ment approaches based on general principals 
' of cognitive behaviour therapy. According to 
Kuipers (1996) CBT has the following main 
goals: 
1) To reduce the distress and interference that 
arises from the experience of persistent psy-
chotic symptoms such as delusions and 
hallucinations. 
2) To increase the individual's understanding of 
psychotic disorders and to foster motivation to 
• engage in self-regulation behaviour 
3) To reduce the occurrence of dysfunctional 
emotions and self-defeating behaviour arising 
from feelings of hopelessness, negative 
jself-image or perceived psychological threat. 
I In recent years, CBT has emerged to be 
beneficial in a variety of contexts in 
schizophrenia ranging from promotion of insight 
(Kingdon & Turkington, 1991) , modifications 
of hallucinations and delusions (Fowler et al., 
1995; Chadwick et al, 1996; Haddock & Slade, 
1996; Chadwick & Birchwood, 1994; Kingdon 
et al., 1994; Persaud & Marks, 1995; Kuipers 
et al., 1997; Garety et al., 1997). The CBT 
techniques used in dealing with drug resistant 
hallucinations in schizophrenia patients include 
pragmatic and practical suggestions, use of ear 
plugs ordiversional activities such as listening 
to music (Nelson et al., 1991; Fowler et al., 
1995; Nelson, 1995). In a randomised 
controlled trial, Kuipers et al.(1997) and Garety 
et al. (1997) have shown that individual CBT 
on a weekly or fortnightly basis was effective in 
reducing distressing impact of psychotic 
symptoms and helped in improving mood and 
engagement in activities. It was also shown that 
good outcome is strongly predicted in patients 
with persistent delusions by cognitive measures. 
Garety et al. (1997) identified cognitive 
flexibility and number of recent hospital 
admissions as predictors of good outcome in 
patients receiving CBT. 
Subsumed under the broad label of CBT 
are various approaches targeted at all or any 
of the goals as mentioned above by Kuipers 
(1996). Cognitive coping behavioural strategies 
attempt to equip the clients and their 
caregivers with adaptive ways of dealing with 
distress due to psychotic symptoms. Relabelling 
and psychoeducation strategies help the 
individual patient to relabel psychotic 
experiences such that the patient is able to 
accept that the experiences that he has are not 
unique to him alone but occur to other patients. 
Some work has been done in evolving 
techniques for modification of delusional beliefs 
by Shapiro & Ravenette (1959), Watts et 
al.(1973> and Chadwick & Lowe (1990). Other 
strategies that are being developed are the 
techniques of CBT that help to reduce or modify 
dysfunctional assumptions on the part of the 
patients and their caregivers. However, these 
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deal of data about their efficacy are available. 
2. Family Interventions : Psycho-educational 
intervention with families of schizophrenia 
patients has a well established literature. 
Family based interventions focus on 
information, communication, support and 
problem solving with a view to ward off relapse. 
Pioneering work by Vaughn & Leff (1976,1981) 
clearly showed that the patients survival 
outside the hospital without relapse was closely 
related to attitudes and behaviour of the family 
members towards the patient. Anderson (1983), 
Falloon et al. (1982) and Falloon & Shanahan 
(1990) showed that behavioural family 
management was effective in reducing 
readmission rates in discharged schizophrenia 
patients. Studies with "high risk" families by Leff 
et al. (1989, 1990) and Hogarty et al. (1986, 
1989) show that family intervention is effective 
in reducing relapse rates in such patients. Family 
interventions have also been shown to reduce 
burden of care, improve patients' functioning in 
social areas and are cost effective to the extent 
that these are less expensive than conventional 
therapies (Falloon et al., 1982,1985; Tamer et 
al., 1988, 1989, 1991, 1994). In more striking 
studies, Telles et al. (1995) and McFarien et al. 
(1995) have shown the beneficial effects of 
family interventions in managing difficult 
patients in the setting of the community. In 
recent reviews of family intervention studies, 
Mari & Streiner (1994), Dixon & Lehman (1995), 
Schooler (1995), Penn & Mueser (1996) and 
Anderson & Adams (1996) concluded that such 
interventions are beneficial in most cases and 
though these strategies are effective, these are 
underused. John (1997) reviewed family inter-
vention work done in India and opined that psy-
chosocial inputs in the management of schizo-
phrenia are important and integral components 
of the care of the patients. 
Many manuals on psychoeducational 
techniques have been published (Falloon et al., 
1985; Barrowclough & Tarrier, 1992; Kuipers et 
al., t992). Psychaeducational techniques'are 
geared towards educating the patients and the 
caregivers, problems solving by the patients and 
family member and emotional processing. 
These are in conjunction with medication. 
Another important aspect of working with 
the families is using techniques for fostering 
better relationships between the consumers i.e. 
the patients and their caregiver and the mental 
health staff engaged in therapy, The need for 
acquiring skills (by the mental health team) for 
promoting positive staff attitude towards the 
patients and caregiveiis crucial for the success 
of any family intervention. It is well recognised 
that the caregivers carry a great deal of burden 
of care, are often under tremendous stress due 
to the sick member of the family and have of-
ten been given negative signals in terms of 
being blamed for the misfortune of the patients. 
They may also have frustrations, despair and a 
fear that things will not work out well. Working 
with such families is not easy. It may be 
difficult to engage them in any therapeutic plans 
as they may be pessimistic about the outcome 
or may perceive the therapeutic process and" 
their involvement too demanding. The attitude 
adopted by the staff influences the 
co-operation one gets from the family members. 
Display of patience, tolerance, willingness to 
persist and flexibility in approach by the staff 
towards the care givers leads to better response 
from the family and encourages a mutually 
trusting partnership between the family and the 
staff (Kuipers & Bebbington, 1990; Birchwood 
& Smith, 1990; Kuipers et al., 1992). 
3. Community based interventions : For 
diverse reason, both in the developed and 
developing countries, community care of 
schizophrenia patients has become a dire 
necessity. In this context, management of 
treatment refractory schizophrenia cases in 
the community poses certain challenges and 
problems. The broad aims of community bashed 
interventions are to improve the quality of life 
of the patients, improve or stabilise mental 
health of the patients and minimise relapses 
and ^hospitalisations. In addition to such 
general measures as good community 
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psychiatry outreach programme and active 
multi-disciplinary team of mental health 
J professionals, some specific measures of 
* community based interventions are as follows: 
Psychiatric research has clearly 
established that relapse in stable 
schizophrenia patients is often preceded by 
prodromal symptoms for weeks and in many 
cases for months. Careful monitoring of the 
patients in follow-up studies has indicated that 
in the weeks before a relapse increase in life 
stresses occurs (Das et al., 1997). Therefore, a 
strategy of " early symptoms and signs 
monitoring" of the patients in the community rs 
likely to pay rich dividends. Common 
prodromal symptoms of relapse are insomnia, 
tension, poor appetite, difficulties in concentra-
tion, restlessness or increasing listlessness, 
depression, irritability, aggression etc. It is also 
recognised that many patients have a set pat-
tern of emergence of symptoms before relapse, 
some thing which has been termed "relapse sig-
nature" (Birchwood & Shepherd, 1992; 
Birchwood et al., 1992). Prompt psychiatric help 
to the patients and the caregivers in such 
situations can often abort a relapse. 
Another community based intervention 
strategy which has significant impact on the rate 
of rehospitalisation in those at greatest risk of 
relapse requiring hospitalisation is descried as 
"assertive outreach programme". Prevention of 
crisis and prompt crisis intervention by trained 
mental health professionals are the main 
techniques used and an help/intervention is 
provided in the patient's home. The programme 
of "assertive outreach" is a staff intensive 
programme i.e. the ratio of staff to patient is 
quite high and staff involved in the delivery of 
services in this programme aggressively and 
assertively pursue the welfare of the patient 
I (Witheridge, 1991; Muijen, t994; Marks et af., 
1994; Wykes, 1994; Wykes & Carson, 1996). 
"Crisis Intervention"^ another alternative 
which can reduce rehospitalisations and" 
clinicaWy and socially benefit the patient (Wuijen 
et al., 1992). 
CONCLUSIONS 
Considerable advances have been made 
in the management of treatment resistant 
schizophrenia patients. The whole phenomenon 
of treatment refractoriness is now better 
understood and refinement in management 
techniques have occurred. These refinements 
include judicious use of conventional and 
atypical antipsychotics coupled with a wide 
array of psychosocial intervention strategies. 
Further, it is now apparent that these newer 
drugs and psychosocial interventions are 
beneficial to the treatment resistant patients and 
the caregivers in effecting symptomatic 
improvement, reducing chronicity and 
disability, minimising and preventing relapse, 
averting the necessity of rehospitalisations, 
reducing the burden of care and improving the 
quality of life of the patients and their long 
suffering families. Strategies aimed at early 
intervention in the setting of the home of the 
patients are likely to play increasing role in 
decreasing treatment resistant, preventing 
relapses and minimising rehospitalisations. 
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